Intrinsic value of Stericycle - SRCL

Previous Close

$61.47

  Intrinsic Value

$62.07

stock screener

  Rating & Target

hold

+1%

Previous close

$61.47

 
Intrinsic value

$62.07

 
Up/down potential

+1%

 
Rating

hold

We calculate the intrinsic value of SRCL stock by summing up the current values of future distributable cash flows generated by the company and dividing the sum by the number of outstanding shares. As such, the intrinsic value calculation depends entirely on projections. The more accurate your projections of the company's performance are - the more reliable is the intrinsic value calculation result. Please make sure to check the stock valuation input data below and adjust it if necessary. The quality of the output (intrinsic valuation result) is only as good as the quality of the input. See also DISCLAIMERS.

STOCK VALUATION INPUT DATA

Revenue (in 2017), $M
Initial revenue growth rate, %
Terminal revenue growth rate, %
Revenue decline factor
Initial discount rate, %
Discount rate multiplier
Variable cost ratio, %
Fixed operating expenses, $M
Interest rate on debt, %
Effective corporate tax rate, %
Production assets / Revenue, %
Life of production assets, yrs
Working capital / Revenue, %
Revenue / Adjusted assets
Adjusted equity ratio
Cash flow adjustment, % of Revenue
Book value of equity, $M
Shares outstanding, mln
Market capitalization, $bln 5.2

 

FINANCIAL STATEMENTS FORECAST and PRESENT VALUE CALCULATION

Fiscal year
   2018
   2019
   2020
   2021
   2022
   2023
   2024
   2025
   2026
   2027
   2028
   2029
   2030
   2031
   2032
   2033
   2034
   2035
   2036
   2037
   2038
   2039
   2040
   2041
   2042
   2043
   2044
   2045
   2046
   2047

INCOME STATEMENT

 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Revenue growth rate, %
  2.00
  2.30
  2.57
  2.81
  3.03
  3.23
  3.41
  3.57
  3.71
  3.84
  3.95
  4.06
  4.15
  4.24
  4.31
  4.38
  4.44
  4.50
  4.55
  4.59
  4.64
  4.67
  4.70
  4.73
  4.76
  4.78
  4.81
  4.83
  4.84
  4.86
Revenue, $m
  3,653
  3,737
  3,833
  3,940
  4,060
  4,191
  4,334
  4,488
  4,655
  4,833
  5,024
  5,228
  5,445
  5,676
  5,921
  6,181
  6,455
  6,746
  7,053
  7,377
  7,719
  8,079
  8,459
  8,860
  9,282
  9,726
  10,193
  10,685
  11,202
  11,747
Variable operating expenses, $m
  3,196
  3,257
  3,327
  3,406
  3,492
  3,588
  3,692
  3,804
  3,925
  4,055
  3,654
  3,803
  3,961
  4,128
  4,307
  4,495
  4,695
  4,906
  5,129
  5,365
  5,614
  5,876
  6,153
  6,444
  6,751
  7,074
  7,414
  7,771
  8,148
  8,544
Fixed operating expenses, $m
  -1
  -1
  -1
  -1
  -1
  -1
  -1
  -1
  -1
  -1
  -1
  -1
  -1
  -1
  -1
  -1
  -1
  -1
  -2
  -2
  -2
  -2
  -2
  -2
  -2
  -2
  -2
  -2
  -2
  -2
Total operating expenses, $m
  3,195
  3,256
  3,326
  3,405
  3,491
  3,587
  3,691
  3,803
  3,924
  4,054
  3,653
  3,802
  3,960
  4,127
  4,306
  4,494
  4,694
  4,905
  5,127
  5,363
  5,612
  5,874
  6,151
  6,442
  6,749
  7,072
  7,412
  7,769
  8,146
  8,542
Operating income, $m
  457
  480
  507
  536
  569
  604
  643
  685
  731
  780
  1,371
  1,427
  1,486
  1,549
  1,616
  1,687
  1,762
  1,841
  1,925
  2,013
  2,106
  2,205
  2,308
  2,418
  2,533
  2,654
  2,781
  2,915
  3,057
  3,205
EBITDA, $m
  1,625
  1,662
  1,705
  1,753
  1,806
  1,864
  1,928
  1,997
  2,071
  2,150
  2,235
  2,326
  2,422
  2,525
  2,634
  2,749
  2,871
  3,001
  3,137
  3,281
  3,433
  3,593
  3,763
  3,941
  4,128
  4,326
  4,533
  4,752
  4,982
  5,224
Interest expense (income), $m
  89
  148
  153
  158
  164
  171
  178
  186
  195
  205
  215
  226
  238
  250
  264
  278
  293
  309
  326
  344
  363
  383
  404
  426
  450
  475
  501
  528
  557
  588
  619
Earnings before tax, $m
  309
  327
  349
  372
  398
  426
  457
  490
  526
  565
  1,146
  1,189
  1,236
  1,285
  1,338
  1,394
  1,453
  1,515
  1,581
  1,650
  1,723
  1,801
  1,882
  1,968
  2,058
  2,153
  2,253
  2,358
  2,469
  2,586
Tax expense, $m
  84
  88
  94
  100
  107
  115
  123
  132
  142
  152
  309
  321
  334
  347
  361
  376
  392
  409
  427
  446
  465
  486
  508
  531
  556
  581
  608
  637
  667
  698
Net income, $m
  226
  239
  254
  272
  290
  311
  334
  358
  384
  412
  836
  868
  902
  938
  977
  1,017
  1,060
  1,106
  1,154
  1,205
  1,258
  1,314
  1,374
  1,436
  1,502
  1,572
  1,645
  1,722
  1,802
  1,887

BALANCE SHEET

 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Cash and short-term investments, $m
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
Total assets, $m
  7,134
  7,298
  7,486
  7,696
  7,930
  8,186
  8,464
  8,766
  9,091
  9,440
  9,813
  10,212
  10,636
  11,086
  11,565
  12,071
  12,608
  13,175
  13,775
  14,408
  15,075
  15,780
  16,522
  17,304
  18,128
  18,995
  19,908
  20,869
  21,880
  22,943
Adjusted assets (=assets-cash), $m
  7,134
  7,298
  7,486
  7,696
  7,930
  8,186
  8,464
  8,766
  9,091
  9,440
  9,813
  10,212
  10,636
  11,086
  11,565
  12,071
  12,608
  13,175
  13,775
  14,408
  15,075
  15,780
  16,522
  17,304
  18,128
  18,995
  19,908
  20,869
  21,880
  22,943
Revenue / Adjusted assets
  0.512
  0.512
  0.512
  0.512
  0.512
  0.512
  0.512
  0.512
  0.512
  0.512
  0.512
  0.512
  0.512
  0.512
  0.512
  0.512
  0.512
  0.512
  0.512
  0.512
  0.512
  0.512
  0.512
  0.512
  0.512
  0.512
  0.512
  0.512
  0.512
  0.512
Average production assets, $m
  6,279
  6,423
  6,588
  6,774
  6,979
  7,204
  7,450
  7,715
  8,001
  8,309
  8,637
  8,988
  9,361
  9,757
  10,178
  10,624
  11,097
  11,596
  12,123
  12,680
  13,268
  13,888
  14,541
  15,230
  15,955
  16,718
  17,522
  18,367
  19,257
  20,193
Working capital, $m
  -256
  -262
  -268
  -276
  -284
  -293
  -303
  -314
  -326
  -338
  -352
  -366
  -381
  -397
  -414
  -433
  -452
  -472
  -494
  -516
  -540
  -566
  -592
  -620
  -650
  -681
  -714
  -748
  -784
  -822
Total debt, $m
  2,831
  2,927
  3,037
  3,160
  3,297
  3,447
  3,611
  3,787
  3,978
  4,182
  4,401
  4,635
  4,883
  5,147
  5,427
  5,724
  6,039
  6,371
  6,722
  7,093
  7,485
  7,897
  8,332
  8,791
  9,274
  9,782
  10,317
  10,880
  11,472
  12,095
Total liabilities, $m
  4,181
  4,277
  4,387
  4,510
  4,647
  4,797
  4,960
  5,137
  5,327
  5,532
  5,751
  5,984
  6,233
  6,497
  6,777
  7,074
  7,388
  7,721
  8,072
  8,443
  8,834
  9,247
  9,682
  10,140
  10,623
  11,131
  11,666
  12,229
  12,821
  13,444
Total equity, $m
  2,953
  3,021
  3,099
  3,186
  3,283
  3,389
  3,504
  3,629
  3,764
  3,908
  4,063
  4,228
  4,403
  4,590
  4,788
  4,998
  5,220
  5,455
  5,703
  5,965
  6,241
  6,533
  6,840
  7,164
  7,505
  7,864
  8,242
  8,640
  9,058
  9,498
Total liabilities and equity, $m
  7,134
  7,298
  7,486
  7,696
  7,930
  8,186
  8,464
  8,766
  9,091
  9,440
  9,814
  10,212
  10,636
  11,087
  11,565
  12,072
  12,608
  13,176
  13,775
  14,408
  15,075
  15,780
  16,522
  17,304
  18,128
  18,995
  19,908
  20,869
  21,879
  22,942
Debt-to-equity ratio
  0.960
  0.970
  0.980
  0.990
  1.000
  1.020
  1.030
  1.040
  1.060
  1.070
  1.080
  1.100
  1.110
  1.120
  1.130
  1.150
  1.160
  1.170
  1.180
  1.190
  1.200
  1.210
  1.220
  1.230
  1.240
  1.240
  1.250
  1.260
  1.270
  1.270
Adjusted equity ratio
  0.414
  0.414
  0.414
  0.414
  0.414
  0.414
  0.414
  0.414
  0.414
  0.414
  0.414
  0.414
  0.414
  0.414
  0.414
  0.414
  0.414
  0.414
  0.414
  0.414
  0.414
  0.414
  0.414
  0.414
  0.414
  0.414
  0.414
  0.414
  0.414
  0.414

CASH FLOW

 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Net income, $m
  226
  239
  254
  272
  290
  311
  334
  358
  384
  412
  836
  868
  902
  938
  977
  1,017
  1,060
  1,106
  1,154
  1,205
  1,258
  1,314
  1,374
  1,436
  1,502
  1,572
  1,645
  1,722
  1,802
  1,887
Depreciation, amort., depletion, $m
  1,167
  1,182
  1,198
  1,217
  1,238
  1,260
  1,285
  1,311
  1,340
  1,370
  864
  899
  936
  976
  1,018
  1,062
  1,110
  1,160
  1,212
  1,268
  1,327
  1,389
  1,454
  1,523
  1,595
  1,672
  1,752
  1,837
  1,926
  2,019
Funds from operations, $m
  1,393
  1,421
  1,453
  1,489
  1,528
  1,571
  1,618
  1,669
  1,724
  1,783
  1,700
  1,767
  1,838
  1,914
  1,995
  2,080
  2,170
  2,265
  2,366
  2,473
  2,585
  2,703
  2,828
  2,959
  3,098
  3,244
  3,397
  3,558
  3,728
  3,907
Change in working capital, $m
  -5
  -6
  -7
  -8
  -8
  -9
  -10
  -11
  -12
  -13
  -13
  -14
  -15
  -16
  -17
  -18
  -19
  -20
  -21
  -23
  -24
  -25
  -27
  -28
  -30
  -31
  -33
  -34
  -36
  -38
Cash from operations, $m
  1,398
  1,427
  1,460
  1,496
  1,536
  1,580
  1,628
  1,680
  1,736
  1,795
  1,713
  1,781
  1,854
  1,930
  2,012
  2,098
  2,189
  2,286
  2,388
  2,495
  2,609
  2,728
  2,855
  2,987
  3,127
  3,275
  3,430
  3,593
  3,764
  3,945
Maintenance CAPEX, $m
  -616
  -628
  -642
  -659
  -677
  -698
  -720
  -745
  -772
  -800
  -831
  -864
  -899
  -936
  -976
  -1,018
  -1,062
  -1,110
  -1,160
  -1,212
  -1,268
  -1,327
  -1,389
  -1,454
  -1,523
  -1,595
  -1,672
  -1,752
  -1,837
  -1,926
New CAPEX, $m
  -122
  -144
  -165
  -185
  -205
  -225
  -245
  -266
  -286
  -307
  -329
  -351
  -373
  -397
  -421
  -446
  -472
  -499
  -528
  -557
  -588
  -620
  -653
  -688
  -725
  -763
  -804
  -846
  -890
  -936
Cash from investing activities, $m
  -738
  -772
  -807
  -844
  -882
  -923
  -965
  -1,011
  -1,058
  -1,107
  -1,160
  -1,215
  -1,272
  -1,333
  -1,397
  -1,464
  -1,534
  -1,609
  -1,688
  -1,769
  -1,856
  -1,947
  -2,042
  -2,142
  -2,248
  -2,358
  -2,476
  -2,598
  -2,727
  -2,862
Free cash flow, $m
  661
  655
  652
  652
  654
  657
  662
  669
  678
  688
  554
  567
  582
  598
  615
  634
  655
  677
  701
  726
  753
  782
  812
  845
  879
  916
  954
  995
  1,038
  1,083
Issuance/(repayment) of debt, $m
  89
  96
  110
  123
  137
  150
  163
  177
  191
  204
  219
  233
  248
  264
  280
  297
  314
  332
  351
  371
  391
  413
  435
  458
  483
  508
  535
  563
  592
  623
Issuance/(repurchase) of shares, $m
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
Cash from financing (excl. dividends), $m  
  89
  96
  110
  123
  137
  150
  163
  177
  191
  204
  219
  233
  248
  264
  280
  297
  314
  332
  351
  371
  391
  413
  435
  458
  483
  508
  535
  563
  592
  623
Total cash flow (excl. dividends), $m
  750
  751
  762
  775
  790
  807
  826
  846
  868
  893
  773
  800
  830
  862
  895
  931
  969
  1,009
  1,052
  1,097
  1,144
  1,194
  1,247
  1,303
  1,362
  1,424
  1,489
  1,558
  1,630
  1,706
Retained Cash Flow (-), $m
  -56
  -68
  -78
  -87
  -97
  -106
  -115
  -125
  -135
  -144
  -155
  -165
  -176
  -187
  -198
  -210
  -222
  -235
  -248
  -262
  -276
  -292
  -307
  -324
  -341
  -359
  -378
  -398
  -418
  -440
Prev. year cash balance distribution, $m
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
Cash flow adjustment, $m
  21
  22
  22
  23
  24
  24
  25
  26
  27
  28
  29
  30
  31
  33
  34
  36
  37
  39
  40
  42
  44
  46
  48
  51
  53
  56
  58
  61
  64
  67
Cash available for distribution, $m
  693
  683
  684
  688
  694
  701
  710
  721
  734
  748
  618
  636
  654
  675
  697
  721
  747
  774
  804
  835
  868
  903
  940
  979
  1,021
  1,065
  1,111
  1,160
  1,212
  1,266
Discount rate, %
  7.50
  7.88
  8.27
  8.68
  9.12
  9.57
  10.05
  10.55
  11.08
  11.63
  12.22
  12.83
  13.47
  14.14
  14.85
  15.59
  16.37
  17.19
  18.05
  18.95
  19.90
  20.89
  21.94
  23.04
  24.19
  25.40
  26.67
  28.00
  29.40
  30.87
PV of cash for distribution, $m
  645
  587
  539
  493
  448
  405
  363
  323
  285
  249
  174
  149
  127
  106
  87
  71
  57
  45
  34
  26
  19
  14
  10
  7
  5
  3
  2
  1
  1
  0
Current shareholders' claim on cash, %
  100.0
  100.0
  100.0
  100.0
  100.0
  100.0
  100.0
  100.0
  100.0
  100.0
  100.0
  100.0
  100.0
  100.0
  100.0
  100.0
  100.0
  100.0
  100.0
  100.0
  100.0
  100.0
  100.0
  100.0
  100.0
  100.0
  100.0
  100.0
  100.0
  100.0

Stericycle, Inc. is a business-to-business services provider. The Company focuses on regulated and compliance solutions for healthcare, retail, and commercial businesses. The Company's segments include Domestic and Canada Regulated Waste and Compliance Services (RCS), Domestic Communication and Related Services (CRS), International RCS and All other. The Domestic and Canada RCS and International RCS segments include medical waste disposal, pharmaceutical waste disposal, hazardous waste management, sustainability solutions for expired or unused inventory, secure information destruction of documents and e-media, training and consulting through its Steri-Safe and Clinical Services programs, and other regulatory compliance services. The Domestic CRS segment consists of inbound/outbound communication, automated patient reminders, online scheduling, notifications, product retrievals, product returns and quality audits.

FINANCIAL RATIOS  of  Stericycle (SRCL)

Valuation Ratios
P/E Ratio 25.4
Price to Sales 1.5
Price to Book 1.9
Price to Tangible Book
Price to Cash Flow 9.6
Price to Free Cash Flow 12.7
Growth Rates
Sales Growth Rate 19.3%
Sales - 3 Yr. Growth Rate %
EPS Growth Rate %
EPS - 3 Yr. Growth Rate %
Capital Spending Gr. Rate 18.3%
Cap. Spend. - 3 Yr. Gr. Rate 13.3%
Financial Strength
Quick Ratio 1
Current Ratio 0.1
LT Debt to Equity 102.5%
Total Debt to Equity 105.1%
Interest Coverage 5
Management Effectiveness
Return On Assets 3.7%
Ret/ On Assets - 3 Yr. Avg. 6%
Return On Total Capital 3.5%
Ret/ On T. Cap. - 3 Yr. Avg. 6.3%
Return On Equity 7.4%
Return On Equity - 3 Yr. Avg. 12.3%
Asset Turnover 0.5
Profitability Ratios
Gross Margin 42.2%
Gross Margin - 3 Yr. Avg. 42.5%
EBITDA Margin 18.8%
EBITDA Margin - 3 Yr. Avg. 21.5%
Operating Margin 12.2%
Oper. Margin - 3 Yr. Avg. 16.8%
Pre-Tax Margin 9.2%
Pre-Tax Margin - 3 Yr. Avg. 14%
Net Profit Margin 5.8%
Net Profit Margin - 3 Yr. Avg. 9.2%
Effective Tax Rate 36.6%
Eff/ Tax Rate - 3 Yr. Avg. 34.7%
Payout Ratio 18.9%

SRCL stock valuation input parameters

Revenue. Company's revenue (or sales) is always the starting point of any cash flow forecast. In the SRCL stock intrinsic value calculation we used $3581 million for the last fiscal year's total revenue generated by Stericycle. The default revenue input number comes from 2017 income statement of Stericycle. You may change it if you feel that it should be adjusted for some unusual circumstances that are not expected to be repeated in the future or if you already know (from interim financial statements, for example) that this year's revenue is going to be quite different.

Revenue growth rate. Forecasted future revenue growth rate is the most important input parameter for the intrinsic value calculation. Unlike other input parameters that are reasonably expected to be in line with their historic averages or their historic trends, the revenue growth rate by and large is a wild card: nobody really knows what the company's revenue will be in the future. Of course, the level of unpredictability is different for different industries (utility companies being the most predictable and, thus, less risky).
    We use three input parameters to forecast the revenue growth rate in our SRCL stock valuation model: a) initial revenue growth rate of 2% whose default value is the revenue growth rate in the most recent quarter compared to the quarterly revenue a year ago; b) terminal revenue growth rate of 5% whose default value is chosen to be close to the average nominal (i.e. not adjusted for inflation) GDP growth rate; and c) revenue decline factor of 0.9, which stipulates that revenue growth rate in each forecasted year will be equal to the difference of the revenue growth rate in the preceding year and the terminal revenue growth rate multiplied by this revenue decline factor (with the passage of time the revenue growth rate will be approaching the terminal revenue growth rate, but not quite reaching it - though the difference could be infinitesimally small).
    At the revenue decline factor of 1, the future revenue growth rate is forecasted to be constant and equal to the initial revenue growth rate. The smaller the revenue decline factor, the faster the revenue growth rate will approach the terminal revenue growth.

Discount rate. The discount rate is used for determining the present value of future cash flows: future cash flows are "discounted" as at normal conditions (that translate into positive expected return on investment) one dollar today is worth more than the same dollar in the future. Unlike all other valuation models, we use variable discount rate, i.e. it increases for each consecutive year. This is done to account for higher risk of cash flows coming in further in the future.
    The initial discount rate of 7.5%, whose default value for SRCL is calculated based on our internal credit rating of Stericycle, is applied to the cash flow expected to be received a year from now (well, actually, to be precise, in the financial year following the base year - the last year for which we have financial statements). For each consecutive year the discount rate is multiplied by the discount rate multiplier of 1.05, e.i. each year it increases by 5%. Feel free to change this number to correspond to your level of risk assessment of Stericycle.
    By the way, it is easy to set the discount rate to be constant (this would make comparison with other valuation models easier): just set the discount rate multiplier equal to 1 and chose the magnitude of the initial discount rate to your liking.

Variable cost ratio is the ratio of variable costs (i.e. costs that fluctuate with fluctuation of the volume of production) to the revenue expressed as a percentage. In the calculation of intrinsic value of SRCL stock the variable cost ratio is equal to 87.8%.

Fixed operating expenses is just that - expenses that are not dependant on the volume of production. They are set to $-1 million in the base year in the intrinsic value calculation for SRCL stock. These expenses increase with the level of inflation in subsequent years.

Interest rate on debt is the average all-in rate of interest paid by the company on its debt. It is set at 5.4% for Stericycle.

Corporate tax rate of 27% is the nominal tax rate for Stericycle. In reality, companies find ways to pay much less taxes than that or not to pay them at all.

Cash flow adjustment could be used for any adjustment the investor deems necessary. Most commonly we use this field to account for stock options-related effects in excess of what is reported on the company's income statement. The cash flow adjustment is expressed as a percentage of the revenue, and in the current valuation of the SRCL stock is equal to 0.6%.

Production assets are the company's assets used for manufacturing products or provision of services. In the valuation model input table they are expressed as a percentage of revenue and for SRCL are equal to 171.9%.

Life of production assets of 10 years is the average useful life of capital assets used in Stericycle operations. It is used to calculate yearly capital expenditures needed to keep these assets in good order - we call it the maintenance CAPEX.

Working capital is the difference between the company's current assets and liabilities. In the model we use the ratio of working capital to revenue, which for SRCL is equal to -7%. A negative number means that the company is apt at using financial resources of its suppliers and customers; a large positive number, on the other hand, means that it either provides in-kind financing to others or is not good at managing its inventories.

Book value of equity - $2897 million for Stericycle - is used in calculation of the "floor" for intrinsic valuation based on the discounted cash flow (DCF) method. Even if the prospects are very bad for a company, its assets could always be sold now for their current fair market value.

Shares outstanding of 85 million for Stericycle is needed to calculate the intrinsic value of one share.

Market capitalization is used here only for reference purposes and as a quick check that the share price and the number of shares outstanding numbers are correct - something especially to be cognizant about at stock splits. So, the market capitalization of Stericycle at the current share price and the inputted number of shares is $5.2 billion.

RELATED COMPANIES Price Int.Val. Rating
SMED Sharps Complia 3.29 0.22  str.sell
WM Waste Manageme 90.85 62.52  sell
CLH Clean Harbors 63.03 51.00  hold
ECOL US Ecology 71.00 32.08  sell

COMPANY NEWS

▶ Why Stericycle Inc Stock Is Sinking Today   [Aug-03-18 11:39AM  Motley Fool]
▶ Stericycle (SRCL) Tops Q2 Earnings Estimates   [Aug-02-18 06:00PM  Zacks]
▶ Stericycle: 2Q Earnings Snapshot   [04:55PM  Associated Press]
▶ Is Stericycle Inc (NASDAQ:SRCL) Undervalued?   [Jun-27-18 09:03AM  Simply Wall St.]
▶ 10 Newest Stocks in the Wide-Moat Focus Index   [Jun-20-18 06:00AM  Morningstar]
▶ Product Recalls: Big Brother or Caring for One Another?   [Jun-12-18 09:00AM  PR Newswire]
▶ Stericycle to Participate in Two Investor Events in June   [Jun-05-18 05:00PM  GlobeNewswire]
▶ Stericycle: 1Q Earnings Snapshot   [May-03-18 04:23PM  Associated Press]
▶ Stericycle to Participate in Two Investor Events   [Apr-18-18 04:30PM  GlobeNewswire]
▶ Following sale of CJ Advertising, Arnie Malham hits the books   [Mar-27-18 12:30PM  American City Business Journals]
▶ Stericycle, Inc. Announces Changes to Board of Directors   [Mar-21-18 06:00PM  GlobeNewswire]
▶ Why Stericycle Stock Is Sinking Today   [Feb-22-18 01:36PM  Motley Fool]
▶ Stericycle: Restructuring Weighs, Shares Attractive   [Feb-21-18 10:10PM  Morningstar]
▶ Stericycle shares fall as earnings miss   [05:02PM  MarketWatch]
▶ Stericycle misses 4Q profit forecasts   [04:21PM  Associated Press]
▶ Stericycle, Inc. to Host Earnings Call   [12:45PM  ACCESSWIRE]
▶ Stericycle to Participate in Two Investor Events in March   [Feb-07-18 04:02PM  GlobeNewswire]
▶ T Rowe Price Equity Income Fund Establishes 4 New Positions   [Jan-16-18 01:31PM  GuruFocus.com]
▶ 6 Stocks With Negative Performances   [Dec-20-17 02:56PM  GuruFocus.com]
▶ New Strong Sell Stocks for December 1st   [Dec-01-17 08:56AM  Zacks]
▶ Stocks That Fell to 3-Year Lows in the Week of Nov. 24   [Nov-25-17 03:35PM  GuruFocus.com]
▶ New Strong Sell Stocks for November 21st   [Nov-21-17 09:31AM  Zacks]
▶ New Strong Sell Stocks for November 10th   [Nov-10-17 08:48AM  Zacks]
▶ Stericycle Sell-Off Overdone   [07:00AM  Morningstar]
▶ Stericycle Inc. Stumbled Backwards in Q3   [10:00AM  Motley Fool]
▶ Stericycle shares down 9% after quarterly sales miss   [Nov-08-17 04:55PM  MarketWatch]
▶ Stericycle misses Street 3Q forecasts   [04:17PM  Associated Press]
▶ Stericycle, Inc. to Host Earnings Call   [03:20PM  ACCESSWIRE]
▶ ETFs with exposure to Stericycle, Inc. : November 3, 2017   [Nov-03-17 12:34PM  Capital Cube]
▶ Stericycle to Present at NASDAQ Conference in December   [Nov-02-17 04:02PM  GlobeNewswire]
▶ ETFs with exposure to Stericycle, Inc. : October 24, 2017   [Oct-24-17 09:43AM  Capital Cube]
Follow us on:   twitter   twitter   twitter   twitter

ASSET ALLOCATION

About X-FIN       Site news       Privacy policy       Terms of use       FAQ

Copyright © X-FIN.com 2005-2018. All rigths reserved.